Abstract: A methodology to track patient usage of an autoinjector (AI) device, and to an external or electronic adaptor (eAdaptor) adapted to be used with the AI are disclosed. The eAdaptor contains sensors (including but not limited to a temperature sensor, a sound sensor, a vibration sensor and a magnetic sensor system), a display, a microprocessor, a real time clock, and communication systems that enables the eAdaptor to capture and confirm autoinjector (AI) use, as well as injection information, and transmit such information wirelessly to a smart phone or any other data receiving system or device. Also disclosed are an internal logic to operate the eAdaptor and a smart device APP that pairs with the internal logic to guide the patients with graphical user interface (GUI) displays on the smart device.

Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.

Abstract: A smart plunger rod adapted to push a medication out of a syringe is disclosed. The plunger rod comprises a shaft sized and dimensioned to act on a piston on the syringe and a finger actuated head portion containing at least two subunits of a wireless sensor. In a pre-activation configuration, the subunits are spaced apart from each other by a physical barrier and the wireless sensor is non-operational. In a post-activation configuration, the subunits are connected to each other and the sensor is operational to send a signal. A user activates the finger actuated head portion to reversibly move the physical barrier and moves the plunger rod from the pre-activation configuration to the post-activation configuration. The signal sent by the sensor comprises information relating to ejecting the medication out of the syringe, and is received by a remote receiver.

Abstract: A methodology to track patient usage of an autoinjector (AI) device, and to an external or electronic adaptor (eAdaptor) adapted to be used with the AI are disclosed. The eAdaptor contains sensors (including but not limited to a temperature sensor, a sound sensor, a vibration sensor and a magnetic sensor system), a display, a microprocessor, a real time clock, and communication systems that enables the eAdaptor to capture and confirm autoinjector (AI) use, as well as injection information, and transmit such information wirelessly to a smart phone or any other data receiving system or device. Also disclosed are an internal logic to operate the eAdaptor and a smart device APP that pairs with the internal logic to guide the patients with graphical user interface (GUI) displays on the smart device.

Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.

Abstract: A device configured to delivery medication is disclosed. The device contains a plurality of sensors, including a magnetic proximity sensor and a temperature sensor. The proximity magnetic sensor can detect whether all the medication has been injected into a patient. The temperature sensor can ascertain whether the temperature of the medication has reached a predetermined or proper level for injection. The device also contains a locking device that can lock the device when the temperature of the medication is below this proper temperature and can automatically unlock the device when the temperature reaches or exceeds this proper temperature.

Abstract: This invention discloses pre-filled syringes and adjustable or movable dose limit fittings that cooperate with the plunger rod to titrate dosage, and methods for using same.

Abstract: Pharmaceutical formulations comprising perindopril or its salts, isomers, enantiomers, polymorphs, metabolites, solvates, hydrates, and mixtures thereof, and at least one surface stabilizer. Also disclosed are methods of stabilizing perindopril in the formulations, and polyoxyethylene-polyoxypropylene block copolymers as surface stabilizers.

Abstract: An electrotransport system for delivery of lisuride or a pharmaceutically acceptable salt thereof. The system has a donor electrode assembly, a counter electrode assembly, and a controller electrically connected to the donor electrode assembly and the counter electrode assembly. The donor electrode assembly has a donor reservoir that contains a lisuride salt. The controller is electrically connected to the donor and counter electrode assemblies and is operatable for controlling current for the electrotransport.

Abstract: An electrotransport system for delivery of a cationic drug. The system has a donor anodic reservoir having an insoluble biocompatible polymeric anion source embedded in the reservoir. The anion source has precipitating anions that can precipitate out metal ions generated from sacrificial metal of the anode during electrotransport.

Abstract: An electrotransport system for delivery of an electrotransport cationic drug. The system has an anode that has a precipitating anion source. The precipitating anions from the precipitating anion source combines with metal ions generated from sacrificial metal of the anode during electrotransport to form precipitates. Metal that can form the metal ions are embedded in the anode.

Abstract: A silicon comprising film and its method of fabrication is described. The silicon comprising film is grown on a substrate. A hexachlorodisilane (HCD) source gas is one of the reactant species used to form the silicon comprising film. The silicon comprising film is formed under a pressure between 10 Torr and 350 Torr.

Abstract: A silicon comprising film and its method of fabrication is described. The silicon comprising film is grown on a substrate. A hexachlorodisilane (HCD) source gas is one of the reactant species used to form the silicon comprising film. The silicon comprising film is formed under a pressure between 10 Torr and 350 Torr.

Abstract: An oxide and an oxynitride films and their methods of fabrication are described. The oxide or the oxynitride film is grown on a substrate that is placed in a deposition chamber. A silicon source gas (or a silicon source gas with a nitridation source gas) and an oxidation source gas are decomposed in the deposition chamber using a thermal energy source. A silicon oxide (or an oxynitride) film is formed above the substrate wherein total pressure for the deposition chamber is maintained in the range of 50 Torr to 350 Torr and wherein a flow ratio for the silicon source gas (or the silicon source gas with the nitridiation source gas) and the oxidation source gas is in the range of 1:50 to 1:10000 during a deposition process.

Abstract: An oxide and an oxynitride films and their methods of fabrication are described. The oxide or the oxynitride film is grown on a substrate that is placed in a deposition chamber. A silicon source gas (or a silicon source gas with a nitridation source gas) and an oxidation source gas are decomposed in the deposition chamber using a thermal energy source. A silicon oxide (or an oxynitride) film is formed above the substrate wherein total pressure for the deposition chamber is maintained in the range of 50 Torr to 350 Torr and wherein a flow ratio for the silicon source gas (or the silicon source gas with the nitridiation source gas) and the oxidation source gas is in the range of 1:50 to 1:10000 during a deposition process.